EA202191427A1 - Каннабиноидное соединение типа каннабидиола - Google Patents

Каннабиноидное соединение типа каннабидиола

Info

Publication number
EA202191427A1
EA202191427A1 EA202191427A EA202191427A EA202191427A1 EA 202191427 A1 EA202191427 A1 EA 202191427A1 EA 202191427 A EA202191427 A EA 202191427A EA 202191427 A EA202191427 A EA 202191427A EA 202191427 A1 EA202191427 A1 EA 202191427A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cbd
cannabinoid
cannabidiol
cannabinoid compound
type
Prior art date
Application number
EA202191427A
Other languages
English (en)
Inventor
Джеффри Гай
Фолкер Кнапперц
Бенджамин Уэлли
Ройстон Грей
Жаклин Силия
Амеша Пател
Ханна Стрэйкер
Original Assignee
ДжиДаблЮ РИСЕРЧ ЛИМИТЕД
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ДжиДаблЮ РИСЕРЧ ЛИМИТЕД filed Critical ДжиДаблЮ РИСЕРЧ ЛИМИТЕД
Publication of EA202191427A1 publication Critical patent/EA202191427A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/11—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/68—Purification; separation; Use of additives, e.g. for stabilisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к каннабиноидному соединению типа каннабидиола (CBD) для применения в качестве лекарственного средства. Каннабиноид типа CBD, каннабидиол-С4 (CBD-C4), представляет собой природный каннабиноид, который в незначительных количествах содержится в растении каннабис. Кроме того, каннабиноид можно получить синтетическим путем. В настоящем документе представлены данные, демонстрирующие эффективность CBD-C4 на моделях заболевания. Кроме того, описан способ производства CBD-C4.
EA202191427A 2018-11-21 2019-11-20 Каннабиноидное соединение типа каннабидиола EA202191427A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1818935.7A GB2579179A (en) 2018-11-21 2018-11-21 Cannabidiol-type cannabinoid compound
PCT/GB2019/053284 WO2020104796A1 (en) 2018-11-21 2019-11-20 Cannabidiol-type cannabinoid compound

Publications (1)

Publication Number Publication Date
EA202191427A1 true EA202191427A1 (ru) 2021-08-25

Family

ID=64739993

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191427A EA202191427A1 (ru) 2018-11-21 2019-11-20 Каннабиноидное соединение типа каннабидиола

Country Status (13)

Country Link
US (1) US20220016048A1 (ru)
EP (1) EP3883563A1 (ru)
JP (1) JP2022511742A (ru)
KR (1) KR20210094000A (ru)
CN (1) CN113226305A (ru)
AU (1) AU2019382961A1 (ru)
BR (1) BR112021009815A2 (ru)
CA (1) CA3119907A1 (ru)
EA (1) EA202191427A1 (ru)
GB (1) GB2579179A (ru)
IL (1) IL283234A (ru)
MX (1) MX2021005919A (ru)
WO (1) WO2020104796A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
CN111943813B (zh) * 2019-05-17 2023-04-14 上海特化医药科技有限公司 大麻二酚类化合物的制备方法
GB201918846D0 (en) * 2019-12-19 2020-02-05 Gw Res Ltd Oral cannabinoid formulations
CA3168491A1 (en) * 2020-01-24 2021-07-29 Perkinelmer Health Sciences, Inc. Cannabinoid derivatives
CN114644547A (zh) * 2020-12-21 2022-06-21 云南汉盟制药有限公司 一种大麻二酚和/或次大麻二酚的制备方法
WO2022238699A1 (en) 2021-05-12 2022-11-17 GW Research Limited 6-hydroxy-cannabidiol-c4
AU2022273928A1 (en) 2021-05-12 2023-11-09 GW Research Limited Derivatives of cannabidiol-c4 for the treatment of epilepsy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441617B2 (en) 2013-03-15 2019-10-15 Biotech Institute, Llc Breeding, production, processing and use of medical cannabis
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
JP2018505912A (ja) * 2014-12-12 2018-03-01 オーハイ エナジェティクス ピービーシー マイクロカプセル化カンナビノイド組成物
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
EP3150264A1 (de) * 2015-09-30 2017-04-05 Bionorica Ethics GmbH Vakuumdestillation zur anreicherung von cbd
GB2548873B (en) * 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10053407B2 (en) * 2016-06-01 2018-08-21 S&B Pharma, Inc. Crystalline cannabidivarin
GB2551985B (en) * 2016-07-01 2019-01-30 Gw Res Ltd Novel formulation
IL248149B (en) * 2016-09-29 2020-03-31 Garti Nissim Formulations of dilutable cannabinoids and processes for their preparation
MX2019013327A (es) * 2017-05-08 2020-07-27 Inmed Pharmaceuticals Inc Formulación para administración ocular de fármacos.
GB201806953D0 (en) * 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations

Also Published As

Publication number Publication date
IL283234A (en) 2021-07-29
GB201818935D0 (en) 2019-01-02
AU2019382961A1 (en) 2021-06-10
EP3883563A1 (en) 2021-09-29
BR112021009815A2 (pt) 2021-08-17
CA3119907A1 (en) 2020-05-28
MX2021005919A (es) 2021-06-30
KR20210094000A (ko) 2021-07-28
CN113226305A (zh) 2021-08-06
JP2022511742A (ja) 2022-02-01
US20220016048A1 (en) 2022-01-20
WO2020104796A1 (en) 2020-05-28
GB2579179A (en) 2020-06-17

Similar Documents

Publication Publication Date Title
EA202191427A1 (ru) Каннабиноидное соединение типа каннабидиола
BR112019003024A2 (pt) plantas e métodos para aumentar e diminuir a síntese de canabinoides
MX2017015304A (es) Plantas de cannabis que tienen expresion modificada de acido tetrahidrocannabinolico sintasa.
EA201792613A1 (ru) Модуляторы cot и способы их применения
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
BR112018001400A2 (pt) compostos, processo para a síntese dos compostos, composição, utilização de um composto, método para o combate dos fungos e sementes
MX2022006046A (es) Compuesto cannabinoide tipo cannabidiol.
BR112016024383A2 (pt) processo para a recuperação de óleo
BR112015018278A2 (pt) método para aprimoramento de tolerância à tensão de estiagem de um grão de cereal
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
BR112017004231A2 (pt) processo para produzir um precipitado estável enriquecido em ficobiliproteínas
MX2021005474A (es) Plantas con perfil de cannabinoides enriquecido con cannabidiol.
MX2020004232A (es) Composiciones de cannabinoides y sus metodos de uso.
EA201690144A1 (ru) Способы модулирования размера семян и органов у растений
BR112019006760A2 (pt) produção acelerada de calos embriogênicos, embriões somáticos e métodos de transformação relacionados
CL2015002376A1 (es) Fibra de madera acetilada
BR112018007394A2 (pt) processo para produzir uma suspensão aquosa de carbonato de cálcio precipitado, suspensão aquosa de carbonato de cálcio precipitado, produto, carbonato de cálcio precipitado, e, uso de uma suspensão aquosa de carbonato de cálcio precipitado
BR112022009539A2 (pt) 6-hidroxi canabidiol para uso, composição para uso como medicamento, e, processo
MX2022005931A (es) Compuesto cannabinoide tipo cannabidiol.
BR112017007948A2 (pt) síntese de tetraidropirano-4-ol-2,4-dissubstituído e quiralmente enriquecido e seus derivados.
MX2022005933A (es) Compuesto cannabinoide tipo cannabidiol.
BR112016018594B8 (pt) Método para produção do derivado de 2-aciliminopiridina
CO2020002617A2 (es) Método para la producción de plántulas de caña de azúcar
AR095087A1 (es) Cuantificación de señales de audio adaptables por tonalidad de baja complejidad
EA201791397A1 (ru) СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ